West Virginia University Logo

Disease Site: Brain Cancer

11 protocol(s) meet the specified criteria

  • A221101A Phase III Randomized, Double-Blind Placebo Controlled Study of Armodafinil (Nuvigil®) To Reduce Cancer-Related Fatigue in Patients with Glioblastoma Multiforme
  • A221208Randomized Phase II Study: Corticosteroids + Bevacizumab vs Corticosteriods + Placebo for Radionecrosis after Radiosurgery for Brain Mets
  • COG-ACNS0332COG-ACNS0332 - Efficacy of Carboplatin Administered Concomitantly With Radiation and Isotretinoin as a Pro-Apoptotic Agent in Other Than Average Risk Medulloblastoma/PNET Patients: A Groupwide Phase III Study
  • COG-ACNS0831ACNS0831- Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients with Newly Diagnosed Ependymoma Ages 1 to 21 years
  • COG-ACNS1422A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients
  • COG-ANBL00B1Neuroblastoma Biology Studies
  • EAY131Molecular Analysis for Therapy Choice (MATCH)
  • INTRAGO-IIA Multicenter Randomized Phase III Trial on Intraoperative Radiotherapy in Newly Diagnosed Glioblastoma Multiforme (INTRAGO II)
  • LOXO-TRK-15002A Phase II Basket Study of Oral TRK Inhibitor LOXO-101 in Subjects with NTRK Fusion-Positive Tumors
  • N0577Phase III Intergroup Study of Temozolomide versus Radiotherapy with Concomitant and Adjuvant Temozolomide versus Radiotherapy with Adjuvant PCV chemotherapy in Patients with 1p/19q Codeleted Anaplastic Glioma
  • TG511-15-01A Phase 2/3 Randomized, Open Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma